Duncan Steele

Dr. Duncan Steele

Bill & Melinda Gates Foundation, Seattle, Washington, USA
orcid

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2012 in The Lancet Infectious Diseases
Verified
Journal Article
Open access
JTJacqueline Tate
Jacqueline Tate
ABAnthony H Burton
Anthony H Burton
CBCynthia Boschi-Pinto
Cynthia Boschi-Pinto
DSDuncan Steele
Duncan Steele
JDJazmin Duque
Jazmin Duque
UPUmesh D Parashar
Umesh D Parashar
WHO recommends routine use of rotavirus vaccines in all countries, particularly in those with high mortality attributable to diarrhoeal diseases. To establish the burden of life-threatening rotavirus disease before the introduction of a rotavirus vaccine, we aimed to update the estimated number of deaths worldwide in children younger than 5 years due to diarrhoea attributable to rotavirus infection. We used PubMed to identify studies of at least 100 children younger than 5 years who had been admitted to hospital with diarrhoea. Additionally, we required the studies to have a data collection midpoint of the year 2000 or later, to be done in full-year increments, and to assesses diarrhoea attributable to rotavirus with EIAs or polyacrylamide gel electrophoresis. We also included data from countries that participated in the WHO-coordinated Global Rotavirus Surveillance Network (consisting of participating member states during 2009) and that met study criteria. For countries that have introduced a rotavirus vaccine into their national immunisation programmes, we excluded data subsequent to the introduction. We classified studies into one of five groups on the basis of region and the level of child mortality in the country in which the study was done. For each group, to obtain estimates of rotavirus-associated mortality, we multiplied the random-effect mean rotavirus detection rate by the 2008 diarrhoea-related mortality figures for countries in that group. We derived the worldwide mortality estimate by summing our regional estimates. Worldwide in 2008, diarrhoea attributable to rotavirus infection resulted in 453,000 deaths (95% CI 420,000-494,000) in children younger than 5 years-37% of deaths attributable to diarrhoea and 5% of all deaths in children younger than 5 years. Five countries accounted for more than half of all deaths attributable to rotavirus infection: Democratic Republic of the Congo, Ethiopia, India, Nigeria, and Pakistan; India alone accounted for 22% of deaths (98,621 deaths). Introduction of effective and available rotavirus vaccines could substantially affect worldwide deaths attributable to diarrhoea. Our new estimates can be used to advocate for rotavirus vaccine introduction and to monitor the effect of vaccination on mortality once introduced.

1 October 2018 in JAMA Pediatrics
Verified
Journal Article
Open access
PDF file
CTChristopher Troeger
Christopher Troeger
IKIbrahim A. Khalil
Ibrahim A. Khalil
PRPuja C. Rao
Puja C. Rao
SCShujin Cao
Shujin Cao
BBBrigette F. Blacker
Brigette F. Blacker
RRRobert C. Reiner
Robert C. Reiner
Diarrheal disease was the fourth leading cause of death among children younger than 5 years in 2015, responsible for nearly 500 000 deaths.1,2 Quiz Ref ID Furthermore, rotavirus infection was responsible for 29.3% (95% uncertainty interval [UI], 24.6%-35.9%) of all diarrheal deaths among children younger than 5 years in 2015 (146 500 deaths; 95% UI, 118 000-183 500).2 Diarrhea-associated mortality has decreased since 1990 by nearly 65% in part because of improvements in safe water and sanitation and reductions in undernutrition among children younger than 5 years.2 Sustained efforts to scale and implement effective interventions must remain the long-term goal to alleviate the global diarrhea burden. In response to the urgent need to prevent avertable diarrhea episodes and their associated mortality, the World Health Organization (WHO) recommended that rotavirus vaccines be included in immunization programs in the European region and the Americas in 2006, a recommendation that was extended to all regions worldwide in 2009.3 In addition, Gavi, the Vaccine Alliance actively supports rotavirus vaccination by subsidizing the cost of vaccination in eligible countries.3

1 November 2018 in The Lancet Infectious Diseases
Verified
Journal Article
Open access
IKIbrahim A Khalil
Ibrahim A Khalil
CTChristopher Troeger
Christopher Troeger
BBBrigette F Blacker
Brigette F Blacker
PRPuja C Rao
Puja C Rao
ABAlexandria Brown
Alexandria Brown
RRRobert C Reiner
Robert C Reiner
Shigella and enterotoxigenic Escherichia coli (ETEC) are bacterial pathogens that are frequently associated with diarrhoeal disease, and are a significant cause of mortality and morbidity worldwide. The Global Burden of Diseases, Injuries, and Risk Factors study 2016 (GBD 2016) is a systematic, scientific effort to quantify the morbidity and mortality due to over 300 causes of death and disability. We aimed to analyse the global burden of shigella and ETEC diarrhoea according to age, sex, geography, and year from 1990 to 2016. We modelled shigella and ETEC-related mortality using a Bayesian hierarchical modelling platform that evaluates a wide range of covariates and model types on the basis of vital registration and verbal autopsy data. We used a compartmental meta-regression tool to model the incidence of shigella and ETEC, which enforces an association between incidence, prevalence, and remission on the basis of scientific literature, population representative surveys, and health-care data. We calculated 95% uncertainty intervals (UIs) for the point estimates. Shigella was the second leading cause of diarrhoeal mortality in 2016 among all ages, accounting for 212 438 deaths (95% UI 136 979-326 913) and about 13·2% (9·2-17·4) of all diarrhoea deaths. Shigella was responsible for 63 713 deaths (41 191-93 611) among children younger than 5 years and was frequently associated with diarrhoea across all adult age groups, increasing in elderly people, with broad geographical distribution. ETEC was the eighth leading cause of diarrhoea mortality in 2016 among all age groups, accounting for 51 186 deaths (26 757-83 064) and about 3·2% (1·8-4·7) of diarrhoea deaths. ETEC was responsible for about 4·2% (2·2-6·8) of diarrhoea deaths in children younger than 5 years. The health burden of bacterial diarrhoeal pathogens is difficult to estimate. Despite existing prevention and treatment options, they remain a major cause of morbidity and mortality globally. Additional emphasis by public health officials is needed on a reduction in disease due to shigella and ETEC to reduce disease burden. Bill & Melinda Gates Foundation.

1 August 2010 in The Lancet
Verified
Journal Article
Closed access
GAGeorge E Armah
George E Armah
SSSamba O Sow
Samba O Sow
RBRobert F Breiman
Robert F Breiman
MDMichael J Dallas
Michael J Dallas
MTMilagritos D Tapia
Milagritos D Tapia
KNKathleen M Neuzil
Kathleen M Neuzil

1 August 2010 in The Lancet
Verified
Journal Article
Closed access
KZK Zaman
K Zaman
DADang Duc Anh
Dang Duc Anh
JVJohn C Victor
John C Victor
SSSunheang Shin
Sunheang Shin
YUYunus
Yunus
MCMax Ciarlet
Max Ciarlet

26 April 2016 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
BLBenjamin A. Lopman
Benjamin A. Lopman
DSDuncan Steele
Duncan Steele
CKCarl D. Kirkwood
Carl D. Kirkwood
UPUmesh D. Parashar
Umesh D. Parashar
Globally, norovirus is associated with approximately one-fifth of all diarrhea cases, with similar prevalence in both children and adults, and is estimated to cause over 200,000 deaths annually in developing countries. Norovirus is an important pathogen in a number of high-priority domains: it is the most common cause of diarrheal episodes globally, the principal cause of foodborne disease outbreaks in the United States, a key health care–acquired infection, a common cause of travel-associated diarrhea, and a bane for deployed military troops. Partly as a result of this ubiquity and burden across a range of different populations, identifying target groups and strategies for intervention has been challenging. And, on top of the breadth of this public health problem, there remain important gaps in scientific knowledge regarding norovirus, especially with respect to disease in low-income settings. Many pathogens can cause acute gastroenteritis. Historically, rotavirus was the most common cause of severe disease in young children globally. Now, vaccines are available for rotavirus and are universally recommended by the World Health Organization. In countries with effective rotavirus vaccination programs, disease due to that pathogen has decreased markedly, but norovirus persists and is now the most common cause of pediatric gastroenteritis requiring medical attention. However, the data supporting the precise role of norovirus in low- and middle-income settings are sparse. With vaccines in the pipeline, addressing these and other important knowledge gaps is increasingly pressing. We assembled an expert group to assess the evidence for the global burden of norovirus and to consider the prospects for norovirus vaccine development. The group assessed the evidence in the areas of burden of disease, epidemiology, diagnostics, disease attribution, acquired immunity, and innate susceptibility, and the group considered how to bring norovirus vaccines from their current state of development to a viable product that will benefit global health.